Skip to Content


In the US, Tiagabine (tiagabine systemic) is a member of the drug class gamma-aminobutyric acid reuptake inhibitors and is used to treat Bipolar Disorder and Seizures.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Antiepileptic agent

Chemical Name

(-)-(R)-1-[4,4-Bis(3-metyl-2-tienyl)-3-butenyl]nipecotic acid

Foreign Names

  • Tiagabinum (Latin)
  • Tiagabin (German)
  • Tiagabine (French)
  • Tiagabina (Spanish)

Generic Names

Brand Names

  • Gabitril
    Teva Italia, Italy; Teva Pharmaceuticals, Poland
  • Tiabine
    Taiwan Biotech, Taiwan
  • Gabitril
    Cephalon, United States; LENIS, Slovenia; Noventure, Spain; Orphan, Australia; Teva, Belgium; Teva, Greece; Teva Pharma, Portugal; Teva Santé, France; Torrex, Czech Republic; Torrex Chiesi, Bulgaria; Torrex Chiesi, Lithuania
  • Tiagabine Hydrochloride Sun
    Sun Pharma, United States


BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.